Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques

Overview
This study evaluates anti-CD20 pre-treatment for enhancing SIV-specific CAR-T cell therapy in macaques. CAR-T cells were manufactured using G-Rex® 6-well plates for expansion. While anti-CD20 treatment increased initial CAR-T expansion, the cells failed to persist long-term, and viral loads were not significantly affected.
What this paper found
Anti-CD20 pre-treatment of SIV-infected rhesus macaques before CD4-MBL-CAR/CXCR5 T-cell infusion was associated with greater follicular CAR-T expansion but did not improve persistence or lower viral load. Animals on antiretroviral therapy received 7 mg/kg anti-CD20 seven days before infusion, which depleted blood CD20+ cells almost completely and lymph node CD20+ cells partially. Follicular CAR-T cells rose a median 15.2-fold between days 2 and 6 in depleted animals versus 8.1-fold in non-depleted animals, and nearly all were Ki67+. Depleted animals showed prolonged elevated IL-6, one animal developed cytokine release syndrome and was euthanized at day 2, and CAR-T cells disappeared rapidly.
Note: Small cohort; the authors note that the number of depleted/CAR-T animals was too small to expect statistical significance in the comparison of fold expansion.
Overall, a single low dose anti-CD20 pre-treatment may effectively enhance the proliferation and accumulation of CAR-T cells at viral reservoir sites, but this treatment requires inclusion of IL-6 inhibitors to prevent CRS — Mary S. Pampusch, Emily N. Sevcik, Zoe E. Quinn, Brianna C. Davey, James M. Berg, Ian Gorrell-Brown, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Pamela J. Skinner, Frontiers in Immunology
Study details
- Authors
- Mary S. Pampusch, Emily N. Sevcik, Zoe E. Quinn, Brianna C. Davey, James M. Berg, Ian Gorrell-Brown, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Pamela J. Skinner
- Institution
- Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, Minnesota, United States · Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, United States
- Journal
- Frontiers in Immunology
- Year
- 2023
- G-Rex® model(s)
- G-Rex®6 Well Plate
- Cell type(s)
- CAR T Cells
- Application area
- Infectious disease
- Study phase
- Preclinical
How G-Rex® was used
After retroviral transduction of autologous rhesus PBMCs, the CD4-MBL-CAR/CXCR5 T cells were moved into G-Rex® 6 well plates and expanded for 4 days in medium containing 50 U/ml IL-2. Cells were then collected, washed and resuspended at 2 × 10^7 cells/mL in PBS with 10% autologous serum for intravenous infusion at doses of 0.1 to 2.3 × 10^8 cells/kg.
Explore related
Full citation
Pampusch MS, Sevcik EN, Quinn ZE, et al. Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques. Front Immunol. 2023;14:1101446.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.